• 1 GP Road, Osisioma, Aba, Abia State, Nigeria
  • info@eecdgroup.com
  •   +234 903 350 9001

NAFDAC's attainment of WHO Maturity Level 3 Status underscores its commitment to ensuring domestic regulatory approval for new pharmaceutical products in Nigeria while facilitating international trade. Additionally, the upgrading of health infrastructure in response to evolving healthcare needs ensures a conducive environment for pharmaceutical innovation and development. With established infrastructure for Artificial Intelligence in the health sector and robust regulations governing pharmaceuticals and food, Nigeria stands as a promising destination for pharmaceutical investment.

Sector Specific Incentives

Tax relief for Research & Development Pioneer status – Tax Holiday Capital allowances

Industry Tailored Benefits

Remittance of proceeds (net of all taxes) in the event of sale or liquidation of the enterprise Total repatriation of capital should the investor choose to relocate elsewhere

Investment Opportunities:

The expanding pharmaceutical landscape in Nigeria presents diverse investment avenues. From the establishment of Medical Parks and Super Specialist Hospitals to the manufacturing of Laboratory consumables, opportunities abound for investors seeking to capitalize on the country's growing healthcare sector. Furthermore, Nigeria's potential to emerge as a manufacturing hub for drug production, coupled with ongoing initiatives for research and development, underscores the lucrative prospects for investors looking to contribute to the prevention and treatment of both communicable and non-communicable diseases.

Regulatory Authorities

National Agency for Food & Drug Administration – NAFDAC

Need any help?

We are here to help our customer any time. You can call on 24/7 To Answer Your Question.

(012) 6679545